Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Pioglitazone/metformin hydrochloride
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 1103
- Registration Number
- NCT02024971
Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
Phase 3
Withdrawn
- Conditions
- Type 2 Diabetes MellitusChronic Kidney Disease
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Takeda
- Registration Number
- NCT02015780
Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2018-11-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3222
- Registration Number
- NCT02016183
Pioglitazone Special Drug Use Surveillance "Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2019-01-24
- Lead Sponsor
- Takeda
- Target Recruit Count
- 18223
- Registration Number
- NCT02002975
Pioglitazone Tablets Special Drug Use Surveillance "Combined Use of Biguanides / Long-term Treatment"
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- Takeda
- Target Recruit Count
- 899
- Registration Number
- NCT02003014
Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2018-12-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 742
- Registration Number
- NCT01993927
Alogliptin/Pioglitazone (Liovel) Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Alogliptin/Pioglitazone
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3281
- Registration Number
- NCT01990300
Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms
Completed
- Conditions
- Gastroesophageal Reflux Disease With Dyspepsia Symptoms
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2016-09-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 14965
- Registration Number
- NCT01990339
Fasiglifam 25 mg BID vs 50 mg QD
Phase 2
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 10
- Registration Number
- NCT01982253
Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy
Phase 4
Completed
- Conditions
- Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 114
- Registration Number
- NCT01972724
© Copyright 2025. All Rights Reserved by MedPath